Published in Breast Cancer (Springer) in June 2024,Sujata Purja, Dung Thuy Nguyen, and Eunyong Kim provide a comprehensive analysis of the evolving landscape of breast cancer epigenetics, emphasizing the therapeutic promise of epi-drugs in transforming treatment paradigms—especially for HER2-negative patients.
The authors reviewed 100 clinical trials involving 22 epigenetic agents, noting that 45% of the candidates are histone deacetylase inhibitors. Tucidinostat and entinostat, in particular, showed notable progression-free survival benefits in HR+/HER2− patients when combined with endocrine therapy. The study also highlights a growing trend toward combining epi-drugs with immunotherapy or targeted agents using sequential dosing strategies.
As clinical interest grows and evidence accumulates, epigenetic therapy is emerging as a key player in moving beyond the one-size-fits-all model toward more personalized, effective treatments for breast cancer.
Read the full article here: https://lnkd.in/d75aubFD
